Press Releases
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update
- Ended the quarter with $51.3 million in cash - expected to fund operations through the end of 2024 including release of topline pivotal trial data- Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients- Progress on development of...
enVVeno Medical Announces New U.S. VenoValve® Patent
- Expanding patent portfolio bolsters protection of the Company's lead product-The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg- There are currently no effective...
enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial DataNine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal...
One-Year VenoValve® Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery
- Previously announced promising results from the first-in-human study demonstrated sustained safety and effectiveness of the VenoValve at 1-year post-implantation- The VenoValve is currently being evaluated in ongoing SAVVE U.S pivotal trial as a potential treatment...
Positive Long-Term VenoValve® First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum
- First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery- No venous ulcer recurrences, relapses of CVI, or safety issues- Improvements in average Reflux, disease manifestations (VCSS), and pain (VAS) endpoints...
enVVeno Medical Announces ISO 13485 Certification
- Achievement of Quality Management System certification represents an important step towards commercializationIRVINE, CA / February 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the...
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference
Live video webcast presentation on Tuesday, January 25th at 1:00 PM ETIRVINE, CA / January 20, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced...
enVVeno Medical to Present at the Virtual Investor Roundtable Event
- Live moderated video webcast discussion with CEO Robert Berman and Marc Glickman, M.D., Senior Vice President and Chief Medical Officer of enVVeno on Tuesday, November 16th at 1:00 PM ETIRVINE, CA / November 16, 2021 / enVVeno Medical Corporation (Nasdaq:NVNO)...
enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Quarter marked by corporate rebranding and strategic prioritization of development programs- Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential treatment for severe deep venous Chronic Venous Insufficiency...
enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial
75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI)Severe CVI Impacts Approximately 2.4 million U.S. Patients with No Current Effective Treatment OptionsIRVINE,...